keyword
MENU ▼
Read by QxMD icon Read
search

Carcinoma cells renal

keyword
https://www.readbyqxmd.com/read/28335045/-imaging-of-metastastic-renal-cell-carcinoma-under-therapy-with-immune-checkpoint-inhibitors
#1
Mike Notohamiprodjo, Hans-Georg Kopp, Jens Bedke
No abstract text is available yet for this article.
April 2017: RöFo: Fortschritte Auf Dem Gebiete der Röntgenstrahlen und der Nuklearmedizin
https://www.readbyqxmd.com/read/28334974/efficacy-and-safety-of-sequential-use-of-everolimus-in-japanese-patients-with-advanced-renal-cell-carcinoma-after-failure-of-first-line-treatment-with-vascular-endothelial-growth-factor-receptor-tyrosine-kinase-inhibitor-a-multicenter-phase-ii-clinical-trial
#2
Masafumi Oyama, Takayuki Sugiyama, Masahiro Nozawa, Kiyohide Fujimoto, Takeshi Kishida, Go Kimura, Noriaki Tokuda, Shiro Hinotsu, Kojiro Shimozuma, Hideyuki Akaza, Seiichiro Ozono
Objective: Many studies have shown the efficacy of everolimus after pretreatment with vascular endothelial growth factor receptor-tyrosine kinase inhibitors. We investigated the efficacy and safety of everolimus as a second-line treatment after the failure of vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy in Japanese patients with advanced renal cell carcinoma. Methods: This was an open-label, multicenter, phase II trial conducted in Japan through the central registration system...
March 1, 2017: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28334518/percutaneous-biopsy-of-the-renal-mass-fna-or-core-needle-biopsy
#3
Chi-Shun Yang, Euna Choi, Muhammad T Idrees, Shaoxiong Chen, Howard H Wu
BACKGROUND: In recent years, there have been increasing indications for percutaneous renal biopsy. Fine-needle aspiration (FNA), with or without core needle biopsy (CB), has been used increasingly in the management of renal tumors at the study institution. METHODS: A computerized search of laboratory records was conducted to retrieve FNA cases of renal masses as well as the correlating CB and/or nephrectomy specimens. The cases spanned a period of 10 years (2006-2015)...
March 23, 2017: Cancer
https://www.readbyqxmd.com/read/28333566/is-change-in-hemoglobin-level-a-predictive-biomarker-of-tyrosine-kinase-efficacy-in-metastatic-renal-cell-carcinoma-a-turkish-oncology-group-study
#4
Cemil Bilir, İbrahim Yıldız, Ahmet Bilici, Mahmut Ucar, Veli Berk, Yaşar Yıldız, Ozan Yazıcı, Gökşen İnanç İmamoğlu, Nuri Karadurmuş, Kezban Nur Pilancı, Erkan Arpacı, Özgür Tanrıverdi, Ebru Karcı, Süleyman Temiz, Erdinc Nayır, Esin Oktay, Pınar Dal, İbrahim Petekkaya, Ceyhun Varım, Hakan Cinemre
BACKGROUND: There are insufficient predictive markers for renal cell carcinoma (RCC). METHODS: A total of 308 metastatic RCC patients were analyzed retrospectively. RESULTS: The increased hemoglobin (Hb) group had significantly higher progression-free survival and overall survival (OS) compared with the decreased Hb group at 11.5 versus 6.35 months (p < .001) and 21.0 versus 11.36 months (p < .001) respectively. The 1- and 3-year OS rates were higher in the Hb increased group, i...
March 23, 2017: Cancer Investigation
https://www.readbyqxmd.com/read/28333136/targeting-3-phosphoinositide-dependent-protein-kinase-1-associated-with-drug-resistant-renal-cell-carcinoma-using-new-oridonin-analogs
#5
Jiancheng Zhou, Eun-Jin Yun, Wei Chen, Ye Ding, Kaijie Wu, Bin Wang, Chunyong Ding, Elizabeth Hernandez, John Santoyo, Rey-Chen Pong, Haiying Chen, Dalin He, Jia Zhou, Jer-Tsong Hsieh
The current agents used for renal cell carcinoma (RCC) only exhibit the moderate response rate among patients. Development of drug resistance eventually fuels the need of either more potent drugs or new drugs to target the resistant pathways. Oridonin is a diterpenoid isolated from the Chinese medicinal herb Rabdosia rubescens and has been shown to have antitumor activities in many cancers. We previously developed new synthetic methodologies to modify structurally diversified diterpenoids and designed a series of nitrogen-enriched oridonin analogs...
March 23, 2017: Cell Death & Disease
https://www.readbyqxmd.com/read/28332632/loss-of-chromosome-y-leads-to-down-regulation-of-kdm5d-and-kdm6c-epigenetic-modifiers-in-clear-cell-renal-cell-carcinoma
#6
Madeleine Arseneault, Jean Monlong, Naveen S Vasudev, Ruhina S Laskar, Maryam Safisamghabadi, Patricia Harnden, Lars Egevad, Nazanin Nourbehesht, Pudchalaluck Panichnantakul, Ivana Holcatova, Antonin Brisuda, Vladimir Janout, Helena Kollarova, Lenka Foretova, Marie Navratilova, Dana Mates, Viorel Jinga, David Zaridze, Anush Mukeria, Pouria Jandaghi, Paul Brennan, Alvis Brazma, Jorg Tost, Ghislaine Scelo, Rosamonde E Banks, Mark Lathrop, Guillaume Bourque, Yasser Riazalhosseini
Recent genomic studies of sporadic clear cell renal cell carcinoma (ccRCC) have uncovered novel driver genes and pathways. Given the unequal incidence rates among men and women (male:female incidence ratio approaches 2:1), we compared the genome-wide distribution of the chromosomal abnormalities in both sexes. We observed a higher frequency for the somatic recurrent chromosomal copy number variations (CNVs) of autosomes in male subjects, whereas somatic loss of chromosome X was detected exclusively in female patients (17...
March 23, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28331985/one-month-assessment-of-renal-cell-carcinoma-treated-by-everolimus-using-fdg-pet-ct-predicts-progression-free-and-overall-survival
#7
Hiroki Ito, Keiichi Kondo, Takashi Kawahara, Tomohiro Kaneta, Ukihide Tateishi, Daiki Ueno, Kazuhiro Namura, Kazuki Kobayashi, Yasuhide Miyoshi, Yasushi Yumura, Kazuhide Makiyama, Narihiko Hayashi, Hisashi Hasumi, Kimito Osaka, Yumiko Yokomizo, Jun-Ichi Teranishi, Yusuke Hattori, Tomio Inoue, Hiroji Uemura, Masahiro Yao, Noboru Nakaigawa
PURPOSE: We evaluated (18)F-2-fluoro-2-deoxyglucose positron emission tomography/computed tomography (FDG PET/CT) results as outcome predictors for patients with metastatic renal cell carcinoma (RCC) treated by everolimus (EVL), an inhibitor of mammalian target of rapamycin. METHODS: We retrospectively reviewed 30 patients who were treated with EVL for metastatic RCC between May 2010 and March 2015, by evaluating their FDG PET/CT result before and 1 month after starting EVL treatment...
March 22, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28331942/contrast-enhanced-ultrasound-for-differentiating-benign-from-malignant-solid-small-renal-masses-comparison-with-contrast-enhanced-ct
#8
Shu-Ping Wei, Chao-Li Xu, Qing Zhang, Qi-Rui Zhang, Yan-E Zhao, Peng-Fei Huang, Ying-Dong Xie, Chang-Sheng Zhou, Fu-Li Tian, Bin Yang
PURPOSE: The study aimed to compare the diagnostic efficiency of contrast-enhanced ultrasound (CEUS) with that of contrast-enhanced computed tomography (CECT) in the evaluation of benign and malignant small renal masses (SRMs) (<4 cm) confirmed by pathology. METHODS: A total of 118 patients with 118 renal masses smaller than 4 cm diagnosed by both CEUS and CECT were enrolled in this study, including 25 benign lesions and 93 malignant lesions. All lesions were confirmed by histopathologic diagnosis after surgical resection...
March 22, 2017: Abdominal Radiology
https://www.readbyqxmd.com/read/28330808/germline-genetic-biomarkers-of-sunitinib-efficacy-in-advanced-renal-cell-carcinoma-results-from-the-renal-effect-trial
#9
Robert J Motzer, Robert A Figlin, Jean-François Martini, Subramanian Hariharan, Neeraj Agarwal, Chun Xiao Li, J Andrew Williams, Thomas E Hutson
BACKGROUND: Sunitinib, the vascular endothelial growth factor pathway inhibitor, is an established standard-of-care for advanced renal cell carcinoma (RCC). This study aimed to assess correlations between candidate germline single nucleotide polymorphisms (SNPs) and sunitinib efficacy in patients from the RENAL EFFECT trial (NCT00267748), a randomized phase II study in patients with metastatic RCC comparing the 4-weeks-on/2-weeks-off schedule and a continuous daily dosing schedule. PATIENTS AND METHODS: Informed consent for pharmacogenetics research was obtained from 202 out of 289 treated patients in the trial...
February 27, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28330784/vascular-endothelial-growth-factor-vegf-and-vegf-receptor-inhibitors-in-the-treatment-of-renal-cell-carcinomas
#10
REVIEW
Robert Roskoski
One Von Hippel-Lindau (VHL) tumor suppressor gene is lost in most renal cell carcinomas while the nondeleted allele exhibits hypermethylation-induced inactivation or inactivating somatic mutations. As a result of these genetic modifications, there is an increased production of VEGF-A and pro-angiogenic growth factors in this disorder. The important role of angiogenesis in the pathogenesis of renal cell carcinomas and other tumors has focused the attention of investigators on the biology of VEGFs and VEGFR1-3 and to the development of inhibitors of the intricate and multifaceted angiogenic pathways...
March 18, 2017: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://www.readbyqxmd.com/read/28330685/renal-clear-cell-carcinoma-diffusion-tensor-imaging-diagnostic-accuracy-and-correlations-with-clinical-and-histopathological-factors
#11
Q Feng, W Fang, X P Sun, S H Sun, R M Zhang, Z J Ma
AIM: To investigate whether diffusion tensor imaging (DTI) can be used to assess renal clinical histopathology, including the nuclear grade (NG), cell density (CD), and the presence of ki-67. MATERIALS AND METHODS: Thirty patients were enrolled in the study and were confirmed at surgical histopathology to have clear cell renal cell carcinoma (CCRCC). For DTI, a coronal echo-planar imaging sequence was performed (1400 ms repetition time, 76 ms echo time, diffusion direction=6, number of excitations=4; b=0 and 800 s/mm(2), 6 mm section thickness with no intersection gap)...
March 19, 2017: Clinical Radiology
https://www.readbyqxmd.com/read/28329682/the-swi-snf-protein-pbrm1-restrains-vhl-loss-driven-clear-cell-renal-cell-carcinoma
#12
Amrita M Nargund, Can G Pham, Yiyu Dong, Patricia I Wang, Hatice U Osmangeyoglu, Yuchen Xie, Omer Aras, Song Han, Toshinao Oyama, Shugaku Takeda, Chelsea E Ray, Zhenghong Dong, Mathieu Berge, A Ari Hakimi, Sebastien Monette, Carl L Lekaye, Jason A Koutcher, Christina S Leslie, Chad J Creighton, Nils Weinhold, William Lee, Satish K Tickoo, Zhong Wang, Emily H Cheng, James J Hsieh
PBRM1 is the second most commonly mutated gene after VHL in clear cell renal cell carcinoma (ccRCC). However, the biological consequences of PBRM1 mutations for kidney tumorigenesis are unknown. Here, we find that kidney-specific deletion of Vhl and Pbrm1, but not either gene alone, results in bilateral, multifocal, transplantable clear cell kidney cancers. PBRM1 loss amplified the transcriptional outputs of HIF1 and STAT3 incurred by Vhl deficiency. Analysis of mouse and human ccRCC revealed convergence on mTOR activation, representing the third driver event after genetic inactivation of VHL and PBRM1...
March 21, 2017: Cell Reports
https://www.readbyqxmd.com/read/28329636/correlation-between-cancer-incidences-and-google-searches-in-the-united-states
#13
Mackenzie R Wehner, Kevin T Nead, Eleni Linos
IntroductionDespite being highly prevalent, keratinocyte carcinomas (basal cell and squamous cell carcinomas lack nationwide registries. Internet search data has emerged as a new method to evaluate previously difficult to quantify public health outcomes and may be useful in keratinocyte carcinoma research.ObjectiveWe aimed to evaluate whether Google search density correlated with known incidences of common cancers in the United States.MethodsWe used the Center for Disease Control's National Program of Cancer Registries ageTadjusted cancer incidences (2008T2012 ...
September 15, 2016: Dermatology Online Journal
https://www.readbyqxmd.com/read/28328844/clinicopathological-study-on-thyroid-follicular-carcinoma-like-renal-tumor-related-to-serious-hypertension-case-report-and-review-of-the-literature
#14
Hui Wang, Jianpeng Yu, Zhonghua Xu, Gang Li
RATIONALE: Thyroid carcinoma-like tumor of the kidney (TLFCK) is an extremely rare variant of renal cell carcinoma. Most cases were incidentally found, while we report the first case of TLFCK presented with hypertension. PATIENT CONCERNS: A 25-year-old woman was admitted to our hospital presenting with hypertension for ∼20 months, without gross hematuria, weight loss, and flank pain. DIAGNOSES: Imaging studies revealed a right renal mass with multiple calcifications...
March 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28328292/il-6-is-involved-in-malignancy-and-doxorubicin-sensitivity-of-renal-carcinoma-cells
#15
Yanqiang Chen, Jianzhen Liu, Pei Lv, Jiangyan Gao, Mingzheng Wang, Yongjun Wang
Various survival factors such as the pleiotropic cytokine interleukin-6 (IL-6), a major mediator of inflammation and activator of signal transducer and activator of transcription 3 (STAT3), serve to block apoptosis in cancer cells. Our present study revealed that the expression of IL-6, while not other IL-2, IL-4, IL-8, or IL-10, was significantly elevated in resistance of renal carcinoma cells (RCC) when compared with human renal proximal tubule epithelial cell line HK-2. The inhibition of IL-6 by siRNA can suppress the proliferation, migration and invasion of RCC cells and increase the doxorubicin (Dox) sensitivity...
March 22, 2017: Cell Adhesion & Migration
https://www.readbyqxmd.com/read/28328257/differentiating-renal-neoplasms-from-simple-cysts-on-contrast-enhanced-ct-on-the-basis-of-attenuation-and-homogeneity
#16
Nnenaya Agochukwu, Steffen Huber, Michael Spektor, Alexander Goehler, Gary M Israel
OBJECTIVE: The purpose of this study is to compare the attenuation and homogeneity of renal neoplasms with those of cysts on contrast-enhanced CT. MATERIALS AND METHODS: A total of 129 renal neoplasms and 24 simple cysts were evaluated. Two readers determined whether each mass was qualitatively heterogeneous or homogeneous. Mean, minimum, and maximum attenuation values were measured. Statistical analysis was performed. RESULTS: A total of 116 heterogeneous renal cell carcinomas (RCCs) (99 clear cell, four papillary, four oncocytic, seven chromophobe, and two unclassified RCCs), 13 homogeneous RCCs (10 papillary, two oncocytic, and one chromophobe RCC), and 24 cysts (all of which were homogeneous) were evaluated...
April 2017: AJR. American Journal of Roentgenology
https://www.readbyqxmd.com/read/28327953/final-overall-survival-analysis-for-the-phase-ii-record-3-study-of-first-line-everolimus-followed-by-sunitinib-versus-first-line-sunitinib-followed-by-everolimus-in-metastatic-rcc
#17
J J Knox, C H Barrios, T M Kim, T Cosgriff, V Srimuninnimit, K Pittman, R Sabbatini, S Y Rha, T W Flaig, R D Page, J T Beck, F Cheung, S Yadav, P Patel, L Geoffrois, J Niolat, N Berkowitz, M Marker, D Chen, R J Motzer
Background: RECORD-3 compared everolimus and sunitinib as first-line therapy, and the sequence of everolimus followed by sunitinib at progression compared with the opposite (standard) sequence in patients with metastatic renal cell carcinoma (mRCC). This final overall survival (OS) analysis evaluated mature data for secondary end points. Patients and Methods: : Patients received either first-line everolimus followed by second-line sunitinib at progression ( n =  238) or first-line sunitinib followed by second-line everolimus ( n =  233)...
February 21, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28327411/gas6-axl-signaling-in-presence-of-sunitinib-is-enhanced-diversified-and-sustained-in-renal-tumor-cells-resulting-in-tumor-progressive-advantages
#18
Anna Gustafsson, Helena K M Fritz, Björn Dahlbäck
Clear Cell Renal Cell Carcinoma (CCRCC) is a lethal cancer with bad prognosis due to development of chemoresistance and recurrence of more aggressive tumors. Investigation of Gas6-mediated Axl signaling in CCRCC and endothelial cells reveals a Sunitinib resistant Gas6-Axl signaling that is sustained and enhanced and specifically triggers downstream AKT and PRAS40 activation in an intensified manner. Gas6-induced Axl signaling in presence of Sunitinib is also diversified displaying onset of Axl-dependent EGFR and METR activation and activation of classical MAPK pathways...
March 19, 2017: Experimental Cell Research
https://www.readbyqxmd.com/read/28327152/trim8-restores-p53-tumour-suppressor-function-by-blunting-n-myc-activity-in-chemo-resistant-tumours
#19
Francesca Mastropasqua, Flaviana Marzano, Alessio Valletti, Italia Aiello, Giuseppe Di Tullio, Annalisa Morgano, Sabino Liuni, Elena Ranieri, Luisa Guerrini, Giuseppe Gasparre, Elisabetta Sbisà, Graziano Pesole, Antonio Moschetta, Mariano Francesco Caratozzolo, Apollonia Tullo
BACKGROUND: TRIM8 plays a key role in controlling the p53 molecular switch that sustains the transcriptional activation of cell cycle arrest genes and response to chemotherapeutic drugs. The mechanisms that regulate TRIM8, especially in cancers like clear cell Renal Cell Carcinoma (ccRCC) and colorectal cancer (CRC) where it is low expressed, are still unknown. However, recent studies suggest the potential involvement of some microRNAs belonging to miR-17-92 and its paralogous clusters, which could include TRIM8 in a more complex pathway...
March 21, 2017: Molecular Cancer
https://www.readbyqxmd.com/read/28327121/bap1-and-pbrm1-in-metastatic-clear-cell-renal-cell-carcinoma-tumor-heterogeneity-and-concordance-with-paired-primary-tumor
#20
Jeanette E Eckel-Passow, Daniel J Serie, John C Cheville, Thai H Ho, Payal Kapur, James Brugarolas, R Houston Thompson, Bradley C Leibovich, Eugene D Kwon, Richard W Joseph, Alexander S Parker
BACKGROUND: BAP1 and PBRM1 are frequently mutated in primary clear cell renal cell carcinoma (ccRCC) tumors; however, the frequency and clinical relevance of these mutations in metastatic ccRCC tumors is unknown. Additionally, while intra-tumor heterogeneity has been shown to be common in primary ccRCC, little is known regarding heterogeneity in metastatic ccRCC tumors. MATERIALS AND METHODS: We analyzed BAP1 and PBRM1 loss of protein expression in patient-matched primary and metastatic tumors from 97 patients...
March 21, 2017: BMC Urology
keyword
keyword
116101
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"